Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03836261
Title	Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY)
Acronym	AMPLIFY
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Acerta Pharma BV
Indications	chronic lymphocytic leukemia
Therapies	Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| SWE \| SVK \| POL \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BGR \| AUT \| AUS \| ARG